Paul C. Lorigan
Expertise in
6
conditions

Paul C. Lorigan

Alderley Park, 
Manchester, ENG, GB 
Expertise in
6
conditions
Alderley Park, 
Manchester, ENG, GB 

Overview

Paul Lorigan practices practicing medicine in Manchester, United Kingdom.

Mr. Lorigan is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Melanoma, Small Cell Lung Cancer (SCLC), Metastatic Uveal Melanoma, Uveal Melanoma, and Vitrectomy.

He is actively involved in clinical research, co-authoring 234 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Alderley Park, Manchester, ENG, United Kingdom
Other Locations
Wilmslow Road, Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Parallel Arm, Biomarker Driven, Phase II Trial to Determine the Role of Circulating Tumour DNA in Guiding a Switch Between Targeted Therapy and Immune Therapy in Patients With Advanced Cutaneous Melanoma
A Parallel Arm, Biomarker Driven, Phase II Trial to Determine the Role of Circulating Tumour DNA in Guiding a Switch Between Targeted Therapy and Immune Therapy in Patients With Advanced Cutaneous Melanoma
Enrollment Status: Unknown
Publish Date: August 25, 2023
Intervention Type: Other
Study Phase: Phase 2
A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Drug: PLX3397
Study Phase: Phase 2
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3
View 4 Less Clinical Trials

233 Total Publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Frequently Asked Questions about Paul C. Lorigan

Is Paul C. Lorigan a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Paul C. Lorigan is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Paul C. Lorigan participate in research or clinical trials?

Yes. Paul C. Lorigan has published 233 articles and abstracts on conditions like Melanoma. You can view a list of Paul C. Lorigan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lorigan's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile